Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2016', provides in depth analysis on T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted pipeline therapeutics. The report provides comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects - The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Overview 6 Therapeutics Development 7 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Products under Development by Stage of Development 7 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Products under Development by Therapy Area 8 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Products under Development by Indication 9 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Products under Development by Companies 12 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Products under Development by Universities/Institutes 14 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development 22 Amgen Inc. 22 GlaxoSmithKline Plc 23 MacroGenics, Inc. 24 SYNIMMUNE GmbH 25 Tiziana Life Sciences Plc 26 Xencor, Inc. 27 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles 28 foralumab - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Monoclonal Antibodies to Activate CD3 and CD16 and to Inhibit HBsAg for HBV Infection and Oncology - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 NF-CU - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 otelixizumab - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 teplizumab - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 XENP-1138 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 XmAb-13551 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Projects 37 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Featured News & Press Releases 38 May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab 38 Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody 38 Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet 39 Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US 40 Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint 40 Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint 41 Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes 42 Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting 43 Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes 44 Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes 45 Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function 46 Jan 07, 2010: Tolerx Completes Patient Enrollment For DEFEND-1 Phase 3 Clinical Study Of Otelixizumab, For The Treatment Of Type 1 Diabetes 46 Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data At The IDF's 20TH World Diabetes Congress 47 Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data at the IDF's 20TH World Diabetes Congress 48 Jun 16, 2009: MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase II/III Clinical Trial of Teplizumab in Type 1 Diabetes 49 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Amgen Inc., H2 2016 22 Pipeline by GlaxoSmithKline Plc, H2 2016 23 Pipeline by MacroGenics, Inc., H2 2016 24 Pipeline by SYNIMMUNE GmbH, H2 2016 25 Pipeline by Tiziana Life Sciences Plc, H2 2016 26 Pipeline by Xencor, Inc., H2 2016 27 Dormant Projects, H2 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
